Search Results
Aug 13, 2026, 16:01 ET Co-Diagnostics Reports Second Quarter 2026 Financial Results
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Aug 13, 2026, 12:02 ET Pilot Project Between BioCytics and LIDE Biotech
as drug resistance or induced cell death, for cells being treated in in vivo validation studies. Further model studies will involve DNA and RNA sequencing for additional response research such as human anti-tumor immune cell function.BioCytics' COO, Dr. Brent Dixon, says that "working
More news about: BioCytics Inc.
Aug 13, 2026, 10:00 ET Innorna Nominated for 2026 Prix Galien USA Best Startup Award
clinical-stage biotech advancing RNA medicines by accelerating a virtuous cycle of platform and pipeline innovation - improving lives worldwide. Backed by a substantial and growing intellectual property portfolio, the company has built a proprietary, differentiated RNA delivery and engineering platform
More news about: Innorna Co., Ltd.
Aug 13, 2026, 10:00 ET Innorna Nominated for 2026 Prix Galien USA Best Startup Award
clinical-stage biotech advancing RNA medicines by accelerating a virtuous cycle of platform and pipeline innovation - improving lives worldwide. Backed by a substantial and growing intellectual property portfolio, the company has built a proprietary, differentiated RNA delivery and engineering platform
More news about: Innorna Co., Ltd.
Aug 13, 2026, 09:30 ET NeuroSense Issues CEO Letter to Shareholders
is designed to target several key mechanisms that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation, with the potential to inhibit disease progression.About ALSAmyotrophic lateral sclerosis ("ALS") is an incurable neurodegenerative
More news about: NeuroSense
Aug 13, 2026, 08:00 ET Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, today announced it has earned another $15 million milestone payment
More news about: Atrium Therapeutics
Aug 12, 2026, 17:00 ET Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates
EGFR inhibitor-associated rash.Continued advancement of recombinant protein initiatives, including Tobacco Etch Virus (TEV) Protease and T7 RNA Polymerase, expanding the Company's platform into biotechnology research and manufacturing applications.Issued CEO Letter to Shareholders detailing
More news about: Azitra, Inc.
Aug 12, 2026, 09:00 ET Viome Acquires Circulate Health, Closing the Loop Between Early Diagnostics, Precision Nutrition, and Treatment
diseases, cancers, and aging through a deeper understanding of an individual's biology at a molecular level. The Viome PRO division leverages proprietary RNA sequencing technology, exclusively licensed from Los Alamos National Laboratory, and AI to develop non-invasive early detection tests for high-mortality
More news about: Viome Life Sciences
Aug 12, 2026, 09:00 ET Cellular Intelligence Names Single-Cell Biology Pioneer Arjun Raj, Ph.D., Chief Scientific Officer and Scientific Co-Founder
of Pennsylvania. A mathematician turned experimental systems biologist, he co-developed a foundational method for visualizing and counting individual RNA molecules inside single cells. His lab has since made influential contributions to understanding stochastic gene expression, cell identity, rare non-genetic
More news about: Cellular Intelligence
Aug 12, 2026, 06:05 ET RyboDyn Unveils a Hidden Human Proteome and a New Universe of Actionable Cancer Targets
healthy tissue, RyboCypher™, the company's proprietary AI-assisted multi-omics target discovery platform, resolved approximately 8.3 million "dark" RNA isoforms, more than 97% of which are absent from existing databases. Armed with the novel reference transcriptome,
More news about: RyboDyn
Aug 11, 2026, 11:40 ET Unlocking High-Quality NGS Data from Challenging Clinical Samples, Upcoming Webinar Hosted by Xtalks
TORONTO, Aug. 11, 2026 /PRNewswire/ -- Extracting meaningful multi-omic insights from DNA and RNA sequencing data generated from challenging clinical specimens remains a common obstacle in biomarker-driven research and clinical trials. In this webinar,
More news about: Xtalks
Aug 11, 2026, 06:37 ET n6 expands global distribution footprint, bringing iconPCR™ and AutoNorm to more scientists across Europe, the Middle East, and Africa
failure rates, simplify workflows, and scale to higher throughput across applications such as microbiome 16S, FFPE oncology, cfDNA, small RNA, and whole‑genome and RNA‑seq studies."With more than 25 countries now running iconPCR and AutoNorm‑enabled workflows, we're seeing the same pattern repeat,"
More news about: n6
Aug 10, 2026, 08:17 ET Dx&Vx兩月內在拉美連簽兩份材料轉移協議 旗下KRNA技術獲公私領域雙重認可
作關係，推進技術對外授權落地。」關於KRNAKRNA是Dx&Vx自主研發的常溫長效核酸穩定平台，品牌名取自「Kinetic RNA」，已於去年完成商標註冊。該平台可適配多種核酸類產品，涵蓋mRNA疫苗、RNA療法、DNA疫苗、適配體、基因療法以及基因編輯工具等。材料轉移工作完成後，合作方將按照自身內部標準獨立開展穩定性測試，該環節是後續達成技術對外授權協議的關鍵驗證步驟。
More news about: Dx&Vx
Aug 10, 2026, 05:27 ET Dx&Vx Signs Two Material Transfer Agreements in Latin America Within Two Months -- "Technology Validated Across Both Public and Private Sectors"
platform developed by Dx&Vx, trademarked last year under a name reflecting "Kinetic RNA". The platform applies to a wide range of nucleic acid-based modalities, including mRNA vaccines, RNA-based therapeutics, DNA vaccines, aptamers, gene therapies, and gene-editing tools.
More news about: Dx&Vx
Aug 08, 2026, 03:46 ET RiboX Therapeutics Announces FDA IND Clearance for RXIM002, the first Circular RNA-Based in vivo CAR Therapy for Autoimmune Cytopenias
the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias.RXIM002 represents the world's first circular RNA-based in vivo CAR-T therapy achieving FDA IND clearance. RiboX expands its clinical-stage
More news about: RiboX Therapeutics Ltd.
Aug 06, 2026, 11:29 ET NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada
is designed to target several key mechanisms that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation, with the potential to inhibit disease progression.About ALSAmyotrophic lateral sclerosis ("ALS") is an incurable neurodegenerative
More news about: NeuroSense
Aug 06, 2026, 10:30 ET Multiomics Market worth $5.70 billion by 2031 - Exclusive Report by MarketsandMarkets™
Next-generation Sequencing Market by Product (Reagents, Kits, Platforms), Service (CHIP Sequencing, Whole Genome, Methyl, RNA Sequencing), Technology (SBS, Nanopore), Workflow (Sequencing, Data Analysis), Application, Competition - Global Forecast to 2031About MarketsandMarkets™MarketsandMarkets™
More news about: MarketsandMarkets
Aug 06, 2026, 09:30 ET Co-Diagnostics Submits FDA 510(k) Premarket Notification for Upper Respiratory Point-of-Care Test
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Aug 06, 2026, 07:30 ET Ractigen Therapeutics Announces Completion of Enrollment and First Dosing in Phase II Clinical Trial of RAG-17 for SOD1-ALS
TherapeuticsRactigen Therapeutics is a clinical-stage biopharmaceutical company innovating next-generation RNA therapeutics, with a primary focus on small activating RNAs (saRNAs) developed through its clinically validated RNA activation (RNAa) technology. Leveraging proprietary delivery platforms such as SCAD™, LiCO™,
More news about: Ractigen Therapeutics
Aug 06, 2026, 07:00 ET Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update
approved for any indication in any jurisdiction.About INS1202INS1202 is an investigational adeno-associated virus (AAV9) short hairpin RNA (shRNA) construct targeting the human superoxide dismutase type 1 (SOD1) gene. Insmed is developing INS1202 as a potential treatment for patients with
More news about: Insmed Incorporated
Aug 05, 2026, 11:01 ET Cold Spring Harbor Laboratory and Northwell Health lead international cohort of researchers to develop more than 150 next-generation cancer treatment models
material from original tumors along with complete clinical information linked to each sample. Additionally, advanced molecular profiles, such as DNA and RNA sequences, and transcriptomic and epigenetic data are available, allowing scientists to analyze the organoids for a more comprehensive picture of the
More news about: Cold Spring Harbor Laboratory
Aug 05, 2026, 08:00 ET Study Finds Blood-Based Breast Cancer Detection Can Create Value for Patients and Healthcare Systems
cancer detection by measuring the body's RNA response to disease. The company believes the future of cancer detection will be defined not only by detecting cancer earlier, but by improving access to earlier detection for more people. Its proprietary blood RNA platform, Onco-IDTM, is being
More news about: Syantra Inc.
Aug 04, 2026, 10:00 ET New England Biolab® launches Monarch® Mag Cell-free RNA (cfRNA) Extraction Kit to enable total cfRNA isolation from biofluids
New England Biolabs (NEB®) announces the release of the Monarch Mag Cell-free RNA (cfRNA) Extraction Kit, which enables isolation of low-abundance, circulating cell-free RNA (cfRNA) and exome-associated RNA from biofluids including plasma, serum, urine and cerebrospinal fluid. The kit complements
More news about: New England Biolabs, Inc.
Aug 03, 2026, 05:30 ET AusperBio Announces First Patient Dosed in Clinical Study of Investigational HBV Candidate AHB-171
announced initiation of patient dosing in a clinical study evaluating AHB-171, the Company's investigational hepatocyte-targeted small interfering RNA (siRNA) therapeutic candidate for chronic hepatitis B.
More news about: AusperBio Therapeutics Inc.
Jul 31, 2026, 07:00 ET Ractigen Therapeutics Announces U.S. FDA IND Clearance for First-in-Class saRNA Candidate RAG-1C to Treat Proliferative Vitreoretinopathy
TherapeuticsRactigen Therapeutics is a clinical-stage biopharmaceutical company innovating next-generation RNA therapeutics, with a primary focus on small activating RNAs (saRNAs) developed through its clinically validated RNA activation (RNAa) technology. Leveraging proprietary delivery platforms such as SCAD™, LiCO™,
More news about: Ractigen Therapeutics